# US 12,178,839 B2 · Anti-obesity agent, pollakiuria improving agent, and autonomic nervous activity regulator

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,839 B2
- Document ID: US12178839B2
- Status: Granted
- Kind: B2
- Application number: 17/288,197
- Filed: 2019-10-17
- Published: 2021-12-30
- Granted: 2024-12-31
- Earliest claimed: 2018-10-26
- Assignees: Asahi Group Holdings, Ltd.
- Applicants: Asahi Group Holdings, Ltd.
- Inventors: Kohji Ohki; Koki Sato; Kazuhito Ohsawa
- Web page: https://patentgrep.com/patent/US12178839B2

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 11/08: Bronchodilators
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/10: of the bladder
- A61P 25/02: for peripheral neuropathies
- C07K 14/4732: {Casein (in foodstuffs A23J)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

[Problem] The purpose of the present invention is to provide a novel technique associated with anti-obesity improvement. [Solution] The present invention relates to an anti-obesity agent comprising lactononadecapeptide (LNDP, Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu) or a salt thereof. The present invention also relates to a pollakiuria improving agent and an autonomic nerve activity regulator each comprising LNDP.

## Claims

### Claim 1

A method for improving pollakiuria, comprising administering a composition comprising an effective amount of a peptide consisting of the amino acid sequence of Asn-Ile-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu SEQ ID NO: 1 or a salt thereof to a patient-in need of improving pollakiuria.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the peptide or a salt thereof is ingested by the patient in an amount of 0.001 mg to 1 g per day.